Clinical Trial Update: Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD [Phase 2]

View source ↗

Summary

Phase 2 mechanistic study evaluating the effect of the anti-IL-33 antibody itepekimab on airway inflammation in patients with chronic obstructive pulmonary dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• itepekimab (itepekimab)

Snippet

Sponsor: Sanofi | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED